The microbe is mightier than the market

Appointing an economist to save us from superbugs might seem odd but, as with many problems, money is at the root of it

Share

Some mocked David Cameron for selecting a money man rather than a medic to head the Government's antibiotics taskforce. On the surface giving the job to Jim O'Neill, the former chief economist at the investment bankers Goldman Sachs, does seem eccentric.

Drugs which have saved millions of lives over the past century are becoming steadily less effective. Superbugs are developing a resistance to the medicines. Antibiotics, which turned once-fatal diseases into trivial inconveniences, are beginning to be outsmarted by evolving microbes. These resistant superbugs killed 5,000 people in the UK last year – and five times more in Europe, 160 times as many in China and 200 times that number in the United States.

But there is more to this than biochemistry. There are cultural issues too. The problem is "pushy patients" demanding antibiotics they don't need, says England's chief medical officer. Our litigation-mad society makes doctors prescribe unnecessary drugs for fear that they will be sued, other medics say. Or it is ignorant patients who – as Alexander Fleming predicted when he discovered the first antibiotic, penicillin, in 1928 – have provoked bacterial resistance by failing to complete the prescribed course once they start to feel better.

Yet economics raises its myopic head too. Some 70 per cent of antibiotic doses in the United States are given prophylactically to farm animals, to keep them healthy in overcrowded conditions, or to promote tissue growth. Antibiotic growth promoters have been banned in the European Union since 2006 and yet vets in the UK claim they see antibiotics used "willy-nilly" on farms all the time as a preventative measure rather than a treatment.

There is, however, an even bigger financial issue. Germs are developing resistance faster than new antibiotics are being developed mainly because no new antibiotics are being developed at all. That is because there is no money in it for the drug companies. It is this economic model which is the real villain in the erosion of the effectiveness of antibiotics. That is why O'Neill is the right man for the job – if, that is, he can set aside his free-market ideology.

The big problem in the war against antibiotic resistance is what economists call market failure. The cost of bringing one antimicrobial drug to market is between £750m and £1.2bn. Yet the income that brings to a Big Pharma company – for a drug which most people will use only once or twice a year – is small compared to what they can earn from other drugs.

For a start doctors will hold the newest and most potent antibiotics in reserve, for when all else fails, so new drugs are used even less often. By contrast, a medicine such as anti-cholesterol statins, which millions use every day, brings cash in truckloads. So do drugs for which firms can charge massive amounts per dose. A new highly effective treatment for deadly hepatitis C, called Sofosbuvir, is currently $84,000 (£49,000) for a 12-week course in the United States.

This is why no new class of antibiotic has reached the market since 1987. Big Pharma prefers more lucrative areas of activity. In 1990 there were almost 20 antibiotic research and development programmes among the bigger drug companies; today, according to the Infectious Diseases Society of America, there are only a handful. Drug giants Pfizer, Eli Lilly and Bristol-Myers Squibb have switched their focus to cancer and chronic diseases, where drugs command higher prices and are taken for longer. AstraZeneca recently said it would put less money into the activity. Only the Swiss firm Roche has a new offering in development.

The public good demands a new generation of antibiotics. But the market is not providing that. It is not the only area of market failure. There is more money to be made from a drug that allows rich fat people to eat without putting on weight than there is in finding a vaccine for malaria which kills mainly poor people in Africa. GlaxoSmithKline is working on an exciting malaria vaccine called RTS,S but only with a $200m grant from the world's biggest philanthropist, Bill Gates.

The hard truth, which even a free-marketeer such as Cameron has had to confront, is that there are some areas in life where the solutions of the market are nasty, brutish and short term-ist. The common good requires something more than a narrow maximisation of share-holder profit. New models have to be found to draw businesses into a wider social responsibility.

O'Neill will probably say that the National Health Service should pay more for antibiotics on the grounds that though you might only take the drug for a couple of weeks it could extend your life by 50 years. But he also needs to discover mechanisms to create partnerships and greater information-sharing between companies, academic researchers, doctors and regulators. He needs to multiply schemes like the EU's Innovative Medicines Initiative, the Path Malaria Vaccine Initiative or GSK's "open innovation" research-sharing strategy on neglected tropical diseases.

There are things that others can do. Medical professionals could get back to basics; antibiotic-resistant staphylococcus infections in hospitals have been cut by a return to vigilant hand-washing. Consumers could start a campaign to identify and boycott meat which has been plumped up with antibiotics. Governments could find much more cash for relevant university research.

But none of this will be to any avail if the O'Neill commission does not find new business models for the production of antibiotics and other socially essential medicines. Over to you, Jim. We are in a war against microbes, and at present the microbes are winning. A post-antibiotic age is too apocalyptic to contemplate.

Paul Vallely is visiting professor of public ethics at the University of Chester

React Now

Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
iJobs Job Widget
iJobs General

Recruitment Genius: Travel Customer Service and Experience Manager

£14000 - £17000 per annum: Recruitment Genius: The fastest growing travel comp...

Recruitment Genius: Cleaner / Caretaker / Storeman

£15500 - £17680 per annum: Recruitment Genius: A position has become available...

Recruitment Genius: Head of Sales - SaaS B2B

£60000 - £120000 per annum: Recruitment Genius: This conference call startup i...

Recruitment Genius: Web Developer

£25000 - £30000 per annum: Recruitment Genius: This digital and print design a...

Day In a Page

Read Next
A pack of seagulls squabble over discarded food left on the beach at St Ives on July 28, 2015  

Number of urban seagulls in Britain nearly quadruples: Hide food and avoid chicks to stay in gulls’ good books

Tom Bawden
 

Blairites be warned, this could be the moment Labour turns into Syriza

Andrew Grice
Blairites be warned, this could be the moment Labour turns into Syriza

Andrew Grice: Inside Westminster

Blairites be warned, this could be the moment Labour turns into Syriza
HMS Victory: The mystery of Britain's worst naval disaster is finally solved - 271 years later

The mystery of Britain's worst naval disaster is finally solved - 271 years later

Exclusive: David Keys reveals the research that finally explains why HMS Victory went down with the loss of 1,100 lives
Survivors of the Nagasaki atomic bomb attack: Japan must not abandon its post-war pacifism

'I saw people so injured you couldn't tell if they were dead or alive'

Nagasaki survivors on why Japan must not abandon its post-war pacifism
Jon Stewart: The voice of Democrats who felt Obama had failed to deliver on his 'Yes We Can' slogan, and the voter he tried hardest to keep onside

The voter Obama tried hardest to keep onside

Outgoing The Daily Show host, Jon Stewart, became the voice of Democrats who felt the President had failed to deliver on his ‘Yes We Can’ slogan. Tim Walker charts the ups and downs of their 10-year relationship on screen
RuPaul interview: The drag star on being inspired by Bowie, never fitting in, and saying the first thing that comes into your head

RuPaul interview

The drag star on being inspired by Bowie, never fitting in, and saying the first thing that comes into your head
Secrets of comedy couples: What's it like when both you and your partner are stand-ups?

Secrets of comedy couples

What's it like when both you and your partner are stand-ups?
Satya Nadella: As Windows 10 is launched can he return Microsoft to its former glory?

Satya Nadella: The man to clean up for Windows?

While Microsoft's founders spend their billions, the once-invincible tech company's new boss is trying to save it
The best swimwear for men: From trunks to shorts, make a splash this summer

The best swimwear for men

From trunks to shorts, make a splash this summer
Mark Hix recipes: Our chef tries his hand at a spot of summer foraging

Mark Hix goes summer foraging

 A dinner party doesn't have to mean a trip to the supermarket
Ashes 2015: With an audacious flourish, home hero Ian Bell ends all debate

With an audacious flourish, the home hero ends all debate

Ian Bell advances to Trent Bridge next week almost as undroppable as Alastair Cook and Joe Root, a cornerstone of England's new thinking, says Kevin Garside
Aaron Ramsey interview: Wales midfielder determined to be centre of attention for Arsenal this season

Aaron Ramsey interview

Wales midfielder determined to be centre of attention for Arsenal this season
Community Shield: Arsene Wenger needs to strike first blow in rivalry with Jose Mourinho

Community Shield gives Wenger chance to strike first blow in rivalry with Mourinho

As long as the Arsenal manager's run of games without a win over his Chelsea counterpart continues it will continue to dominate the narrative around the two men
The unlikely rise of AFC Bournemouth - and what it says about English life

Unlikely rise of AFC Bournemouth

Bournemouth’s elevation to football’s top tier is one of the most improbable of recent times. But it’s illustrative of deeper and wider changes in English life
A Very British Coup, part two: New novel in pipeline as Jeremy Corbyn's rise inspires sequel

A Very British Coup, part two

New novel in pipeline as Jeremy Corbyn's rise inspires sequel
Philae lander data show comets could have brought 'building blocks of life' to Earth

Philae lander data show comets could have brought 'building blocks of life' to Earth

Icy dust layer holds organic compounds similar to those found in living organisms